Shell stock in focus after Friday slip: buyback tally and a dividend date ahead

February 15, 2026
Shell stock in focus after Friday slip: buyback tally and a dividend date ahead

London, February 15, 2026, 11:05 GMT — The market has closed.

  • Shell ended Friday’s session at 2,872.5 pence, slipping 0.5%.
  • Shell announced new share buybacks on Feb. 13, rolling them out under its updated capital-return program.
  • Next up: oil supply signals, plus Shell’s ex-dividend date on Feb. 19.

Shell (SHEL.L) slipped 0.5% on Friday, closing at 2,872.5 pence after moving in a range from 2,856.0 to 2,890.0 pence. When trading resumes Monday, the conversation shifts back to crude prices and what Shell might signal about returning cash to shareholders. 1

Markets are closed for the weekend, so investors are sizing up what’s likely to shift the tape next—oil news, or the rhythm of mechanical flows from dividends and buybacks. For an integrated oil major, those drivers often pull more weight on share price moves in the short term than any drawn-out strategy discussion.

Shell disclosed another round of share buybacks, snapping up 1,836,150 shares for cancellation on Feb. 13. The purchases took place in both London and Amsterdam, at an average price near £28.71 per share in London and €33.05 in Amsterdam. 2

The buybacks are part of Shell’s $3.5 billion program unveiled Feb. 5, designed to shrink its share count. Shell plans to finish the program before it reports first-quarter results—assuming market conditions allow. 3

Oil prices left the sector with a mixed finish. Brent edged up 0.3% to settle at $67.75 a barrel Friday, while U.S. West Texas Intermediate wrapped up at $62.89. Traders weighed softer U.S. inflation numbers against prospects for additional supply later this year. “Looks like inflation is stabilizing,” said Dennis Kissler, senior vice president of trading at BOK Financial. 4

OPEC+ is weighing a return to boosting output as soon as April, according to sources who spoke to Reuters. Eight major producers are scheduled to gather on March 1. Russian Deputy Prime Minister Alexander Novak pointed out that demand typically begins to climb “from around March and April”. 5

Friday brought a different policy headline. The U.S. loosened sanctions on Venezuela’s energy sector, issuing general licenses that cover Shell as well as Chevron, BP, Eni, and Repsol, according to Reuters. The terms require that royalty and Venezuelan tax payments be routed through a deposit fund controlled by the U.S. 6

Shell investors eyeing dividends have their next date in focus: Feb. 19 is when the stock goes ex-dividend. Anyone buying after that day won’t qualify for the upcoming payout. Payment lands March 30. The company’s schedule pegs May 7 as the day it will announce the first-quarter 2026 dividend call. 7

U.S. investors face a different timetable at the week’s open, with the NYSE shuttered Monday for Washington’s Birthday. That hands London and Amsterdam the first chance to react to any weekend moves in crude, geopolitics, or supply headlines. 8

Still, there’s only so much those short-term props can do. Should traders get a clearer read on rising supply—OPEC+ or maybe even Venezuela—oil could tumble fast. Energy stocks, buybacks or not, usually get dragged with it.

Pressure points are up ahead. Oil traders have their eyes on Shell’s Feb. 19 ex-dividend date, followed by the OPEC+ meeting set for March 1, which could offer more clarity on whether the group will actually move from discussing April output hikes to locking them in.

Stock Market Today

  • Pharmaceutical Closures Market in Australia: Size, Trends, and Forecast to 2035
    April 4, 2026, 6:14 AM EDT. The Pharmaceutical Closures market in Australia covers specialized seals for primary drug containers, ensuring sterility and controlled delivery for various dosage forms. This independent report provides market size, historic development, and forecasts up to 2035. It outlines demand and supply architecture, including manufacturing inputs, regulatory factors, and pricing dynamics. Key commercial segments span type, application, customer, and geography. The study identifies competitive structures, highlighting company capabilities and strategic opportunities for entrants or expansion. Critical risks tied to operations, qualification, and market acceptance are assessed. Intended for manufacturers, investors, and partners, it delivers a comprehensive view of the market, helping stakeholders navigate complexities in this niche pharmaceutical component sector.